Cartesian Therapeutics, Inc. (RNAC)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-08-06) · 99.1 | ||
| 10-Q | Q1-2026 | 8-K (2026-04-30) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-03-09) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-06) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-07) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-08) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-03-13) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-07) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-08) · 99.1 · 99.2 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-08) · 99.1 · 99.2 | ||
| 10-K | FY-2023 | 8-K (2024-03-07) · 99.1 | ||
| 10-Q | Q3-2023 | — |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover Page | ||
| Audit Information | — |
|
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations and Comprehensive Income (loss) | ||
| Consolidated Statements of Operations and Comprehensive Loss | ||
| Consolidated Statements of Changes In Convertible Preferred Stock and Stockholders Deficit | — |
|
| Consolidated Statements of Changes In Stockholders' Equity (deficit) | — |
|
| Consolidated Statements of Changes In Stockholdersâ Deficit | — |
|
| Consolidated Statements of Cash Flows | ||
| Consolidated Statements of Changes In Convertible Preferred Stock and Stockholders Deficit (P) | — |
|
| Consolidated Statements of Changes In Convertible Preferred Stock and Stockholders Equity (deficit) | ||
| Consolidated Statements of Changes In Convertible Preferred Stock and Stockholders Equity (deficit) (P) | ||
| Notes | ||
| Accrued Expenses | ||
| Basis of Presentation | ||
| Collaboration and License Agreements | ||
| Commitments and Contingencies | ||
| Convertible Preferred Stock | ||
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Debt | ||
| Defined Contribution Plan | ||
| Description of The Business | ||
| Employee Benefit Plan | — |
|
| Equity | ||
| Fair Value Measurements | ||
| Goodwill and Indefinite-lived Intangible Assets | — |
|
| Goodwill and Intangible Assets | ||
| Income Taxes | ||
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Investments | ||
| Leases | ||
| Marketable Securities and Investments | ||
| Merger | ||
| Net (loss) Income Per Share | ||
| Net Income (loss) Per Share Allocable To Common Stockholders | — |
|
| Net Loss Per Share | — |
|
| Net Loss Per Share Allocable To Common Stockholders | ||
| Pay Vs Performance Disclosure | ||
| Property and Equipment | ||
| Related-party Transactions | ||
| Restructuring | ||
| Revenue Arrangements | ||
| Segment Information | — |
|
| Segment Reporting | ||
| Series A Preferred Stock | ||
| Stock Incentive Plans | ||
| Subsequent Events | ||
| Summary of Significant Accounting Policies | ||